CORONA DEL MAR, Calif.--(BUSINESS WIRE)--CureDuchenne will sponsor a one-year research program that will validate Dr. Giulio Cossu’s stem cell research under GMP (Good Manufacturing Procedures) conditions. Dr. Cossu’s long-term objective is to conduct phase I/II clinical trials in Duchenne muscular dystrophy (“DMD”) pediatric patients with this novel cell therapy protocol based on intra-arterial delivery of donor mesoangioblasts. The immediate objective of Dr. Cossu is to develop a clinical grade protocol that will allow transplantation of patients with mesoangioblasts in a successive clinical trial. During this study, Dr. Cossu will prepare an IMPD, the European equivalent of a US IND (Investigational New Drug Application), and submit to the Regulatory Authorities for the formal authorization of the clinical trial.
